curcumin/doxorubicin (iMX-110) / Immix Biopharma - LARVOL DELTA

Fmoc-FF Nanogel-Mediated Delivery of Doxorubicin and Curcumin in Thyroid Cancer Cells. (PubMed, Pharmaceutics) - "Comparative studies with CUR-loaded NGs revealed similar internalization and delayed nuclear uptake, highlighting the efficacy of Fmoc-FF NGs in delivering hydrophobic agents. Overall, the data suggest that Fmoc-FF NGs represent a promising strategy for delivering agents with diverse physicochemical properties in TC, enhancing their efficacy and safety and warranting further investigation."

Journal • Endocrine Cancer • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Mitigating doxorubicin-induced hepatotoxicity in male rats: The role of aerobic interval training and curcumin supplementation in reducing oxidative stress, endoplasmic reticulum stress and apoptosis. (PubMed, Sci Rep) - "Both curcumin and AIT significantly reduced DOXO-triggered oxidative damage, ER stress, and apoptosis (P < 0.05), with the latter showing slightly higher effectiveness. Consequently, the combination of AIT with curcumin supplementation exhibits protective effects against chronic hepatotoxicity induced by DOXO, with AIT demonstrating relatively greater efficacy in increasing antioxidant capacity and reducing ER stress and apoptosis."

Journal • Preclinical • Hepatology

A nano drug delivery system loading drugs and chlorin e6 separately to achieve photodynamic-chemo combination therapy. (PubMed, Nanomedicine (Lond)) - "Doxorubicin (DOX) was loaded into the pores of MSNs...Additionally, in vitro experiments suggested that the nanoparticles had pleasing toxicity to various tumor cells and equally positive therapeutic effect when curcumin replaced DOX. Our work suggests that the nanoparticles designed by our strategy have satisfactory combination therapy performance and can enable more chemotherapy drugs to be used in photodynamic-chemo combination therapy."

Journal • Oncology

Liposomal Codelivery of Doxorubicin and Curcumin Sensitizes Antitumor Activity and Reduces Tumor Metastasis. (PubMed, ACS Appl Bio Mater) - "Compared to the conventional DOX treatment, the dual-drug treatment exhibits a significantly improved anticancer effect. In the murine metastasis 4T1 IP tumor model, the dual-drug-encapsulating liposomes successfully suppressed tumor growth and reversed the tumoral effect (omental tumor metastasis, fat, and muscle weight loss) into a normal state."

Journal • Oncology

Human and canine osteosarcoma cell lines: How do they react upon incubation with calcium phosphate-coated lipid nanoparticles carrying doxorubicin and curcumin? (PubMed, Int J Pharm) - "Additionally, the combination treatment led to a further increase in C12DOXO retention when cells were also treated with the P-gp inhibitor verapamil, indicating enhanced efficacy against MDR mechanisms. Notably, canine OSA cells exhibited a distinct response pattern, suggesting the presence of species-specific differences that warrant further investigation."

Journal • Preclinical • Oncology • Osteosarcoma • Sarcoma • Solid Tumor

Fabrication of curcumin-loaded nano-micelles based on quercetin-quarternary ammonium-chitosan (Qu-QCS) conjugate and evaluation of synergistic effect with doxorubicin against breast cancer. (PubMed, Int J Biol Macromol) - "Moreover, the co-treatment of dox with cur-loaded Qu-QCS nano-micelles showed increased anticancer activity and reduced cardiotoxicity. Overall, this study suggests the potential applications of cur-loaded Qu-QCS micelles in the delivery of chemotherapeutic agents and complementary support in combination with chemotherapeutic agents."

Journal • Breast Cancer • Cardiovascular • Oncology • Solid Tumor

Conquering dual challenges: A sialic-modified liposome for targeting activated neutrophils to tackle comorbid lung inflammation and cancer metastasis. (PubMed, J Control Release) - "In this context, we introduce a novel therapeutic approach involving a sialic acid-lipid derivative (SA-PG10-C18) modified doxorubicin-curcumin co-loaded liposome (DOX/CUR-SAL)...The treated animals demonstrated favorable survival conditions, persisting beyond 45 days. This innovative therapeutic strategy offers a novel concept and reference for treating comorbid conditions of tumors and inflammation, thus breaking the clinical impasse where lung inflammation and cancer metastasis have been treated separately."

Journal • Acute Lung Injury • Infectious Disease • Lung Cancer • Oncology • Pneumonia • Respiratory Diseases

Exploiting lignin-based nanomaterials for enhanced anticancer therapy: A comprehensive review and future direction. (PubMed, Int J Biol Macromol) - "Lignin nanoparticles loaded with drugs like curcumin, doxorubicin, camptothecin, and resveratrol have demonstrated the ability to improve drug efficacy, selectively target cancer cells, overcome multidrug resistance, and minimize toxicity in both in vitro and in vivo studies...Future research directions include optimizing lignin nanoparticle formulations for clinical applications, refining targeted delivery mechanisms to cancer cells, and conducting thorough biocompatibility and toxicity assessments. Overall, this review highlights the significant progress made in utilizing lignin-based nanomaterials for cancer therapy and outlines promising areas for further exploration in this rapidly evolving field."

Journal • Review • Oncology

Cytotoxicity of Doxorubicin-Curcumin Nanoparticles Conjugated with Two Different Peptides (CKR and EVQ) against FLT3 Protein in Leukemic Stem Cells. (PubMed, Polymers (Basel)) - "Moreover, DCM-C + E and CM-C + E showed the highest toxicity in KG-1a and EoL-1 cells. Using two peptides likely improves the probability of micelles binding to the FLT3 receptor and induces cytotoxicity in leukemic stem cells."

Journal • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3

Investigation of green synchronous spectrofluorimetric approach for facile sensitive estimation of two co-administered anti-cancer drugs; curcumin and doxorubicin in their laboratory-prepared mixtures, human plasma, and urine. (PubMed, BMC Chem) - "It showed a high percentage of recoveries with minimal RSD values. Additionally, three different tools were utilized to evaluate the greenness of the proposed approach."

Journal • Oncology

Harnessing the therapeutic potential of phytochemicals in neuroblastoma. (PubMed, Biofactors) - "Several studies have used plant-derived bioactive compounds such as phenolics and flavonoids, suggesting modulation of biomolecules and signal transduction pathways involved in neuroblastoma. We reviewed the findings of recent preclinical and clinical studies demonstrating the effects of phytochemicals on neuroblastoma, shedding light on their molecular mechanism of action and potential therapeutic applications."

Journal • Review • CNS Tumor • Neuroblastoma • Oncology • Pediatrics • Solid Tumor

Reduction-Responsive Polyprodrug Nanoplatform Based on Curcumin for Tumor-Targeted Therapy. (PubMed, Curr Drug Deliv) - "The prepared reduction-responsive targeted polymer nanomedical DOX/HAPCS NPs exhibited a synergistic anti-cancer effect, with high drug loading capacity and the ability to release drugs in proportion, making it a promising polymer nanoparticle drug delivery system."

Journal • Oncology

Dual-Drug Loaded Nanobubbles Combined with Sonodynamic and Chemotherapy for Hepatocellular Carcinoma Therapy. (PubMed, Int J Nanomedicine) - "We developed curcumin/doxorubicin-cis-aconitic anhydride-polyethylene glycol nanobubble (C/DCNB) surface modified with acid-sensitive polyethylene glycol (PEG)...In vitro and vivo experiments demonstrate that C/DCNB can facilitate contrast-enhanced ultrasound imaging while simultaneously delivering drugs, enabling both imaging and treatment. The combination of C/DCNB and ultrasound provides an effective strategy for improving the efficiency of HCC therapy and imaging."

Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Curcumin attenuates doxorubicin-induced cardiotoxicity via suppressing oxidative Stress, preventing inflammation and apoptosis: Ultrastructural and computational approaches. (PubMed, Heliyon) - "In cardiac tissue, CMN significantly increased the concentrations of SOD and CAT and significantly decreased the concentrations of MDA and TNF-α. Biochemical and histological studies have demonstrated that CMN has a heart-protective effect that might be related to its antioxidant and anti-inflammatory capabilities."

Journal • Cardiovascular • Inflammation • Oncology • CAT • TNFA

Dual centrifugation as a novel and efficient method for the preparation of lipodisks. (PubMed, Int J Pharm) - "Furthermore, our investigations confirm the efficacy of DC in formulating curcumin and doxorubicin within these lipodisks. For doxorubicin, careful control and optimization of the experimental conditions resulted in formulations displaying an encouraging encapsulation efficiency of 84 % and a favourable drug-to-lipid ratio of 0.13 in the disks."

Journal

Long-Acting Nanohybrid Hydrogel Induces Persistent Immunogenic Chemotherapy for Suppressing Postoperative Tumor Recurrence and Metastasis. (PubMed, Mol Pharm) - "Here, we constructed an injectable curcumin/doxorubicin-loaded nanoparticle (NanoCD) hydrogel, which could effectively inhibit tumor regrowth and metastasis via reshaping the tumor immune microenvironment (TIME) for highly effective postsurgical cancer treatment...Upon being injected into the tumor cavity after resection, the in situ-generated NanoCD@Gel allowed the local release of CUR and DOX in a controlled manner to induce local chemotherapy and persistently activate the antitumor immune response, thereby achieving enhanced immunogenic chemotherapy with reduced systemic toxicity. Our work provides an elegant strategy for persistently stimulating effective antitumor immunity to prevent postsurgical tumor recurrence and metastasis."

Journal • Oncology

A PHASE 1/2A OPEN-LABEL, DOSE-ESCALATION/DOSE EXPANSION SAFETY, TOLERABILITY AND PHARMACOKINETIC STUDY OF IMX-110 IN PATIENTS WITH ADVANCED SOLID TUMORS (CTOS 2023) - "N/A This abstract is submitted under Trials in Progress"

Clinical • Metastases • P1/2 data • PK/PD data • Oncology • Solid Tumor • STAT3

Empowering Cancer Therapy: Comparing PEGylated and Non-PEGylated Niosomes Loaded with Curcumin and Doxorubicin on MCF-7 Cell Line. (PubMed, Bioengineering (Basel)) - "Finally, the MTT results confirmed the biocompatibility and synergistic effect of the simultaneous use of two drugs on cancer cells in the PEGylated niosomal particle. Based on the results, PEGylated niosomal particles can be considered adept vehicles for the simultaneous delivery of different chemotherapy cargoes with synergic interaction to overcome cancer."

Journal • Preclinical • Oncology

IMX-110 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=70 | Active, not recruiting | Sponsor: Immix Biopharma Australia Pty Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Jul 2023 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Oct 2023

Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

Preparation of nano-sized multi-vesicular vesicles (MVVs) and its application in co-delivery of doxorubicin and curcumin. (PubMed, Colloids Surf B Biointerfaces) - "In vivo antitumor experiments demonstrated that nano-sized DOX/CUR@MVVs significantly improved the antitumor activity while reducing the toxic side effects of DOX. Overall, the successful preparation of nano-sized DOX/CUR@MVVs and their potent and low-toxic antitumor effects provide a critical experimental reference for the combined antitumor therapy of MVVs and liposomes."

Journal • Oncology

Immix Biopharma Reports 2nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1b/2a IMX-110 IMMINENT-01 Clinical Trial (GlobeNewswire) - P1b/2a | N=60 | IMMINENT-01 (NCT05840835) | Sponsor: Immix Biopharma, Inc. | "Immix Biopharma...announced its 2nd positive IMX-110 interim update from the Company’s ongoing Phase 1b/2a IMMINENT-01 (NCT05840835) study of IMX-110 in combination with BeiGene's anti-PD-1 antibody tislelizumab. As of the July 7, 2023 data cutoff date, out of 4 relapsed/refractory metastatic colorectal cancer patients treated with IMX-110 + tislelizumab....Tumor shrinkage was observed in 3 out of 4 (75%) patients; 1 out of 4 (25%) experienced tumor control as of the July 7, 2023 clinical data cutoff date. All patients had stage IV relapsed/refractory metastatic colorectal cancer and received 8 median lines of therapy prior to IMX-110 + tislelizumab. Dose Escalation Proceeding: dosing of 2nd dose cohort complete; no drug-related severe adverse events were observed, enabling enrollment of the next higher dose cohort with the goal of establishing the recommended phase 2 dose."

P1/2 data • Trial status • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

ASCO 2023: Improving Genitourinary Cancer Care (Cancer Therapy Advisor) - "'The main finding of the trial is the importance of total cumulative cisplatin dose, as patients who received more than 4 cycles of chemotherapy had better survival than those who received 4 cycles or less. We can conclude that more cisplatin is needed for improved survival,' Dr Bilusic said."

Media quote

Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program (Yahoo Finance) - "Immix Biopharma...announced that it has completed its previously announced 'at-the-market' equity offering program (the 'ATM Offering')....The Company ultimately sold 2,263,868 shares of common stock and generated aggregate gross proceeds before commissions and offering expenses of approximately $5,000,000. ThinkEquity acted as agent for the ATM. The Company intends to use net proceeds from the ATM Offering for its IMX-110 + tislelizumab Phase 1b combination clinical trial, its IMX-110 monotherapy clinical trial, and general corporate purposes."

Financing • Oncology • Solid Tumor

Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=60 | Recruiting | Sponsor: Immix Biopharma, Inc.

New P1/2 trial • Oncology • Solid Tumor

Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data Demonstrating 100% Tumor Shrinkage in Advanced Metastatic Colorectal Cancer at the Lowest Dose of IMX-110 + BeiGene / Novartis Anti-PD-1 Antibody Tislelizumab (GlobeNewswire) - P1b/2a | N=60 | IMMINENT-01 (NCT05840835) | Sponsor: Immix Biopharma, Inc. | "Immix Biopharma, Inc....announced positive early interim clinical trial data: 100% Tumor Shrinkage at 2-months in advanced metastatic colorectal cancer demonstrated by IMX-110 + BeiGene / Novartis anti-PD-1 antibody tislelizumab combination in the first cohort of patients (two out of two first evaluable patients) who received the lowest IMX-110 dose in its ongoing dose escalation 1b/2a clinical trial of IMX-110 + anti-PD-1 antibody tislelizumab (IMMINENT-01), as of the April 14, 2023 data cutoff date."

P1/2 data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor